Artesunate
- Generic Name
- Artesunate
- Brand Names
- Artesunate Amivas
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28O8
- CAS Number
- 88495-63-0
- Unique Ingredient Identifier
- 60W3249T9M
- Background
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin.
Artesunate was granted FDA approval on 26 May 2020.
- Indication
Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients.
- Associated Conditions
- Acute Uncomplicated Plasmodium Falciparum Malaria, Malaria, Cerebral, Severe Malaria
- Associated Therapies
- -
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
- Conditions
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 40
- Registration Number
- NCT00493363
- Locations
- 🇰🇭
Pailin Referal Hospital, Pailin, Cambodia
Artemisinin Resistance in Cambodia
- Conditions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2008-04-30
- Lead Sponsor
- Medical University of Vienna
- Registration Number
- NCT00479206
- Locations
- 🇰🇭
Tasanh Health Center, Tasanh, Batambang, Cambodia
ACT MALI: Treatment of Malaria Based on Combination Therapies
- Conditions
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 780
- Registration Number
- NCT00452907
- Locations
- 🇲🇱
Sanofi-Aventis Administrative Office, Bougoula, Mali
Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance
- Conditions
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT00445796
- Locations
- 🇸🇳
Sanofi-Aventis, Dakar, Senegal
Chloroquine Alone or in Combination for Malaria in Children in Malawi
- Conditions
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2014-08-11
- Target Recruit Count
- 640
- Registration Number
- NCT00379821
- Locations
- 🇲🇼
Blantyre Malaria Project - Ndirande Health Centre, Blantyre, Malawi
Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia
- Conditions
- First Posted Date
- 2006-09-20
- Last Posted Date
- 2006-09-20
- Target Recruit Count
- 360
- Registration Number
- NCT00378625
- Locations
- 🇨🇴
Hospital Ismael Roldan and Centro de Salud San Vicente, Quibdo, Choco, Colombia
Relationship Between HIV and Malaria in Ugandan Children
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00356824
- Locations
- 🇺🇬
Pediatric Infectious Diseases Clinic, Mulago Hospital Complex, Kampala, Uganda
Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh
- Conditions
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 228
- Registration Number
- NCT00356005
- Locations
- 🇧🇩
Sadar Hospital, Bandarban, Bangladesh
Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study
- Conditions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2006-10-24
- Lead Sponsor
- Heidelberg University
- Registration Number
- NCT00354380
- Locations
- 🇧🇫
Nouna District Hospital, Nouna, Burkina Faso
Azithromycin Combination Therapy for Malaria
- Conditions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 120
- Registration Number
- NCT00299208
- Locations
- 🇹🇭
Mahidol University Hospital for Tropical Diseases, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.